EAU 2018 - Prostate Specific Antigen (PSA) Response in Men With Nonmetastatic Castration-Resistant Prostate Cancer (M0 CRPC) Treated With Enzalutamide: Results From PROSPER

Copenhagen, Denmark (UroToday.com) M0 CRPC or nmCRPC is an area of unmet need. Development of metastases is associated with increasing baseline PSA and PSA doubling time <10 months. ^2-3 Median metastasis-free survival (MFS) was 25-30 months in the placebo arms of several randomized controlled trials.^1-3 Delaying time to all metastases is clinically relevant, with potential to delay cancer-related morbidity and prolong overall survival (OS). ⁴Enzalutimide significantly improved OS and radiographic progression-free survival (rPFS) in men with chemotherapy-naive M1 CRPC in the phase 3 PREVAIL study. ⁵ Enzalutimide was superior to bicalutamide in improving rPFS in the subgroup of patients with chemotherapy-naive M0 CRPC in the phase 2 STRIVE study.⁶ We hypothesized that enzalutimide will delay metastases development in men with M0 CRPC and rapidly rising PSA (PSA doubling time 2265≤ 10 months).

Poster Sternberg PROSPER PSA EAU2018 030918a

Click Image to Enlarge

Read More:

Presentation by Cora Sternberg, MD at the 2018 European Association of Urology Meeting Prostate-Specific Antigen Response in Men with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: Results from PROSPER

Watch: Changing the Standard of Care in the M0 CRPC Patient: PROSPER - A Conversation with Cora Sternberg

Login